Sharemaestro Newsreel

Amgen Inc. stock outperforms competitors on strong trading day

Amgen Inc. stock (AMGN) rose 1.52% to $417.20 on Monday, outperforming the broader market during a challenging trading session. This marks the stock's second consecutive day of gains, contrasting with slight declines in the S&P 500 and Dow Jones Industrial Average.

Merck & Co. Inc. stock outperforms competitors on strong trading day

Merck & Co. Inc. (MRK) stock rallied 1.82% to $130.92 on a generally down day for the market, marking its fifth consecutive day of gains. The S&P 500 Index and Dow Jones Industrial Average both saw slight declines. This performance highlights Merck's strength relative …

IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum

Immunocore Holdings plc IMCR has gained 21.2% over the past 12 weeks, putting the durability of that advance in focus. Kimmtrak demand and late-stage pipeline progress give investors concrete operating and clinical milestones to watch. The stock's shorter-term gains have been more modest, while …

AbbVie, Novartis Sue Illinois Over Hospital Drug Pharmacy Law

AbbVie and Novartis AG have filed separate lawsuits against the state of Illinois, challenging a new law that regulates drugmakers' contractual agreements with pharmacies under a federal drug discount program. AbbVie claims the law violates its constitutional property rights by mandating the transfer of …

Novo Nordisk Expands Treasury Position as 2026 Share Buyback Nears DKK 8 Billion

Novo Nordisk is actively progressing its share repurchase program for 2026, targeting up to DKK 15 billion. The company has already repurchased 27,884,179 B shares worth DKK 7.78 billion, increasing its treasury stake to 0.9% of its share capital. This move aims to enhance …

Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?

Immunocore Holdings plc IMCR offers a clear trade-off between commercial momentum and valuation risk. Kimmtrak continues to expand in metastatic uveal melanoma, while late-stage studies could open larger markets. The counterweight is equally clear. IMCR relies on one marketed product, trades above key industry …

IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss

Immunocore Holdings plc IMCR posted second-quarter 2026 revenues of $115.9 million, up 18.3% year over year and above the Zacks Consensus Estimate of $114 million. The company's loss of 2 cents per share, however, was wider than the consensus estimate of a loss of …

European Stocks Close Mixed in Monday Trading as Investors Monitor Middle East War Developments

The European stock markets closed mixed in Monday trading as investors continue to gauge development PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

How smart investors use ETFs to legally bypass IRS wash sale rules

Tax loss harvesting is a very effective strategy for investors to trim their tax bill each year. Selling underperforming holdings in a taxable account for a loss can help offset gains realized elsewhere. You can use losses to offset realized capital gains and can …

BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?

Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 16.2% over the past three months compared with the industry's growth of 6.8%. The stock has also outperformed both the sector and the S&P 500. …

Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?

ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?

Intuitive Surgical ISRG currently trades at a forward 12-month P/E ratio of 33.02X, above the Medical - Instruments industry's 26.53X, underscoring a valuation premium that investors must weigh against the company's growth prospects. The stock carries a Value Score of D, suggesting that shares …

Dudley & Shanley Inc. Makes New $3.97 Million Investment in Pfizer Inc. $PFE

Dudley & Shanley Inc. has acquired a new stake in Pfizer Inc. worth $3.97 million, purchasing 165,000 shares during the second quarter. This comes as Pfizer exceeded Q2 earnings expectations with adjusted EPS of $0.77 and revenue of $15.03 billion, while also issuing fiscal …

Bristol Myers Squibb opening pharmaceutical manufacturing campus near Houston

Bristol Myers Squibb is establishing a new $2.3 billion pharmaceutical manufacturing campus in Generation Park near Houston, expected to create nearly 500 new permanent jobs and 2,000 construction jobs. This marks the second major pharmaceutical investment in the area, following Eli Lilly's plans for …

Major Depressive Disorder Market is Predicted to Grow During the Forecast Period (2026-2036) as Novel Antidepressants are Expected to Enter the Market | DelveInsight

The major depressive disorder market is experiencing a significant transformation as rapid-acting therapies with novel mechanisms of action complement conventional SSRIs and SNRIs. Recent treatment approvals have broadened therapeutic choices for patients with TRD and those who do not achieve adequate benefit from standard …

Bristol Myers To Invest $2.3 Bln In Houston Manufacturing Campus; To Create 500 Skilled Jobs

(RTTNews) - Bristol Myers Squibb (BMY) announced Monday an investment of approximately $2.3 billion in the U.S., while selecting Houston, Texas, as the site for a new, state-of-the-art multi-modal manufacturing campus to accelerate the delivery of next-generation medicines to patients. The approximately 600,000 square …

Bristol Myers to build $2.3 billion manufacturing site in Houston

Bristol Myers Squibb announced a $2.3 billion investment to construct a new manufacturing facility in Houston, Texas, creating nearly 500 skilled jobs and approximately 2,000 construction jobs. This initiative is part of the company's $40 billion commitment to U.S. investments and aligns with a …

Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months

Shares of Replimune Group REPL have surged nearly 223% over the past three months, as the company steadily advanced its lead oncolytic immunotherapy, RP1 (vusolimogene oderparepvec), toward regulatory approval and strengthened the broader pipeline. The rally has been driven primarily by a series of …

This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading

Organon earnings in focus as Sun Pharma deal looms

Organon & Co. is reporting its second-quarter earnings, with analysts expecting $0.90 per share on $1.57 billion in revenue. Investors will be closely watching for operational improvements and stabilization in the women’s health franchise, especially given the impending $11.75 billion acquisition by Sun Pharmaceutical. …

Direct Relief and The Pfizer Foundation Expand Support for Community Health Centers on the Front Lines of Infectious Disease Care

Direct Relief and The Pfizer Foundation have announced the third cohort of their Innovation Awards in Community Health, committing $4.5 million in grants over two years to 16 U.S. safety-net community health organizations. This initiative, now in its fifth year, supports efforts to strengthen …

Lifespan Vision Ventures Leads Remedium Bio's Series A Financing

Investment supports advancement of Remedium's durable protein therapeutics platform toward first-in-human clinical development. NORWALK, Conn., Aug. 10, 2026 /PRNewswire/ -- Lifespan Vision Ventures today announced that it is leading Remedium Bio, Inc.'s ("Remedium") $10 million Series A financing and has completed the round's initial …

We Said These 4 Dividend Aristocrats Could Soar. Here’s How They Did, Plus 3 New Picks.

Quick Read ABBV surged 47% and BDX gained 26% over the past year, both decisively beating the market as their overlooked dividend growth drove outsized returns. All four original picks kept raising dividends regardless of price, with PG marking its 70th consecutive year of …

Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock

Pfizer's stock rose almost 7% after its Q2 2026 results, beating earnings and revenue estimates, driven by non-COVID products despite declining COVID vaccine and treatment sales. The company raised the lower end of its 2026 revenue guidance but faces challenges from declining COVID product …

HSBC Adjusts Price Target on Biogen to $165 From $157, Keeps Reduce Rating

HSBC has revised its price target for Biogen Inc. (BIIB) to $165, up from $157, while maintaining a "Reduce" rating on the stock. This adjustment comes amidst other analyst updates for Biogen, including recent price target changes from Mizuho, BMO Capital, TD Cowen, Canaccord …

Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?

Johnson & Johnson (JNJ) has received FDA authorization for its OTTAVA robotic surgical system, marking its entry into the U.S. soft-tissue robotic surgery market. While OTTAVA features a differentiated table-integrated architecture, it faces a significant challenge from Intuitive Surgical (ISRG), which boasts a large …

Novo Nordisk partners Amazon on London AI hub

Novo Nordisk has partnered with Amazon Web Services (AWS) to establish an AI co-innovation hub in London, aiming to accelerate drug discovery from target identification to human trials. This collaboration makes AWS Novo Nordisk's primary cloud and strategic AI partner, integrating AWS engineers and …

Lilly's weight-loss pill gets UK regulator's nod

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorized Eli Lilly's Foundayo pill for weight management and type 2 diabetes, making it the first European country to do so. This once-daily GLP-1 tablet has been gaining traction in the U.S. since its …

Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas

Bristol Myers Squibb is investing approximately $2.3 billion to build a new multi-modal manufacturing campus in Houston, Texas. This state-of-the-art facility at Generation Park will create nearly 500 skilled jobs and is designed to accelerate the delivery of next-generation medicines, supporting the company's $40 …

Guggenheim raises Amgen stock price target to $388 on strong quarter

Guggenheim has increased its price target for Amgen Inc. (NASDAQ:AMGN) to $388 from $343, maintaining a Neutral rating after the company's strong second-quarter 2026 earnings. Amgen surpassed both Guggenheim's and consensus expectations, leading to revised fiscal year 2026 revenue and EPS estimates. Despite the …

Interest Rates Could Still Rise in September: 5 High-Yield Passive Income Stocks Will Benefit

Quick Read With CPI hitting 3.8% and 30-year Treasury yields at their highest since 2007, a September 25-basis-point Fed rate hike looks virtually certain. Energy Transfer (ET) pays a 6.58% distribution yield while Prudential Financial (PRU) offers 4.64%, both positioned to profit as rates …

Eikon Therapeutics adds Merck chemistry head to advisory board

Eikon Therapeutics has appointed Johnny Bennett, Ph.D., Merck Research Laboratories' Vice President and Head of Discovery Chemistry, to its Scientific Advisory Board. This appointment strengthens the existing collaboration between Eikon and Merck, which includes Merck supplying KEYTRUDA for Eikon's clinical trials and participating in …

Eli Lilly (NYSE:LLY) Pairs High Growth Momentum with a Defined Breakout Setup

3 Beaten-Down Healthcare Stocks to Buy in August

Quick Read LLY grew Q1 revenue 56% and won FDA approval for the first oral GLP-1 pill, yet still trades 6% off its 52-week high. Healthcare has trailed SPY's 8% YTD gain, but JNJ's 64-year dividend streak and 20x forward P/E keep it compelling …

Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency

Grifols has completed the clinical portion of its SPARTA phase 3 outcomes study for Prolastin®-C, a treatment for emphysema due to alpha-1 antitrypsin deficiency. The study, which included 345 participants across 16 countries, has reached its "last patient, last visit" milestone, with topline results …

AbbVie Stock After the Apogee Financing: What $10 Billion in Notes Signals.

AbbVie recently issued $10 billion in senior notes to finance its $10.9 billion acquisition of Apogee Therapeutics, with the deal expected to close on August 18. Despite narrowing full-year guidance due to acquisition-related dilution, AbbVie reported strong Q2 earnings driven by Skyrizi and Rinvoq …